3
Announcements
Trials
Browse
Landscape
Status
Completed
4
Withdrawn
1
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Thyroid Neoplasms
1
Multiple Pulmonary Nodules
1
Multiple Advanced Tumors After PD-1 Therapy Failure
1
Gastritis, Atrophic
1
Desmoid Tumors
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Cancer Pain
1
Barrett Esophagus
1
Adenocarcinoma Of Esophagus
1
Interventions
Specimen Handling
7
Nivolumab
6
pembrolizumab
4
lenvatinib
3
cabozantinib
3
Axitinib
3
vorolanib
2
fludarabine
2
anlotinib
2
Sunitinib
2
Nephrectomy
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Cyclophosphamide
2
Biopsy
2
toripalimab
1
tivozanib
1
sintilimab
1
pazopanib
1
fludarabine phosphate
1
enzalutamide
1
cemiplimab
1
bemarituzumab
1
belzutifan
1
balstilimab
1
atezolizumab
1
abiraterone
1
Zoledronic Acid
1
Saline Solution
1
Rubidium-82
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Carcinoma, Renal Cell
×
Radiofrequency Ablation
×
Clear all
NCT07465458
2026-03-16
RASROP-003
Humanitas Hospital, Italy
Not yet recruiting
226 enrolled